Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 288.13% is 80% above its 5-year average of 159.99%, around the middle of its 5-year range (86.69%–649.18%).
As of the fiscal period ended Tuesday, June 30, 2026. 4.26% above its 12-month average of 276.36%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 288.13%.
RETURN ON EQUITY (ROE)
288.13%
RETURN ON EQUITY (ROE) AVG TTM
276.36%
RETURN ON EQUITY (ROE) AVG 3Y
130.63%
RETURN ON EQUITY (ROE) AVG 5Y
159.99%
RETURN ON EQUITY (ROE) AVG 10Y
87.83%
RETURN ON EQUITY (ROE) AVG 15Y
18.75%
RETURN ON EQUITY (ROE) AVG 20Y
-19.89%
CURRENT VS TTM AVG
+4.26%
CURRENT VS 3Y AVG
+120.56%
CURRENT VS 5Y AVG
+80.09%
CURRENT VS 10Y AVG
+228.05%
CURRENT VS 15Y AVG
+1437.07%
CURRENT VS 20Y AVG
+1548.28%
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 607 covered companies
CURRENT VS SECTOR MEDIAN
+816.57%
vs the sector median at left
Halozyme Therapeutics, Inc.
Market Cap
$13.05B
Return on Equity (ROE)
288.13%
TTM Avg
276.36%
3Y Avg
130.63%
5Y Avg
159.99%
Market Cap
$12.91B
Return on Equity (ROE)
7.78%
TTM Avg
17.97%
3Y Avg
19.27%
5Y Avg
21.22%
Market Cap
$13.20B
Return on Equity (ROE)
-57.18%
TTM Avg
-651.33%
3Y Avg
-315.37%
5Y Avg
-198.08%
Market Cap
$13.25B
Return on Equity (ROE)
N/A
TTM Avg
35.81%
3Y Avg
39.37%
5Y Avg
-92.14%
Market Cap
$12.56B
Return on Equity (ROE)
3.51%
TTM Avg
5.40%
3Y Avg
5.85%
5Y Avg
7.17%
Market Cap
$12.53B
Return on Equity (ROE)
-17.13%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
Market Cap
$12.51B
Return on Equity (ROE)
10.49%
TTM Avg
6.83%
3Y Avg
5.29%
5Y Avg
3.21%
Market Cap
$12.51B
Return on Equity (ROE)
14.35%
TTM Avg
4.54%
3Y Avg
-6.13%
5Y Avg
-2.52%
Market Cap
$12.35B
Return on Equity (ROE)
23.91%
TTM Avg
22.63%
3Y Avg
21.83%
5Y Avg
21.13%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | $13.05B | 288.13% | 276.36% | 130.63% | 159.99% |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.91B | 7.78% | 17.97% | 19.27% | 21.22% |
| Tempus AI, Inc. (TEM)vs › | $13.20B | -57.18% | -651.33% | -315.37% | -198.08% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $13.25B | N/A | 35.81% | 39.37% | -92.14% |
| ICON Public Limited Company (ICLR)vs › | $12.56B | 3.51% | 5.40% | 5.85% | 7.17% |
| Baxter International Inc. (BAX)vs › | $12.53B | -17.13% | -12.46% | -8.76% | -1.37% |
| Penumbra, Inc. (PEN)vs › | $12.51B | 10.49% | 6.83% | 5.29% | 3.21% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.51B | 14.35% | 4.54% | -6.13% | -2.52% |
| Encompass Health Corporation (EHC)vs › | $12.35B | 23.91% | 22.63% | 21.83% | 21.13% |
| Ascendis Pharma A/S (ASND)vs › | $14.24B | 52.97% | 246.13% | 150.31% | 84.65% |
ROE
288.1%
ROA
16.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 288.13% |
| 2026-03-31 | 158.83% |
| 2025-12-31 | 649.18% |
| 2025-09-30 | 118.17% |
| 2025-06-30 | 167.48% |
| 2025-03-31 | 100.64% |
| 2024-12-31 | 122.06% |
| 2024-09-30 | 86.69% |
| 2024-06-30 | 116.54% |
| 2024-03-31 | 179.30% |
| 2023-12-31 | 336.00% |
| 2023-09-30 | 101.90% |
| 2023-06-30 | 154.74% |
| 2023-03-31 | 275.83% |
| 2022-12-31 | 119.04% |
| 2022-09-30 | 217.75% |
| 2022-06-30 | 124.89% |
| 2022-03-31 | 167.11% |
| 2021-12-31 | 204.47% |
| 2021-09-30 | 145.24% |
| 2021-06-30 | 191.00% |
| 2021-03-31 | 241.26% |
| 2020-12-31 | 85.46% |
| 2020-09-30 | 21.74% |
| 2020-06-30 | -37.60% |
| 2020-03-31 | -138.07% |
| 2019-12-31 | -78.72% |
| 2019-09-30 | -16.29% |
| 2019-06-30 | -16.46% |
| 2019-03-31 | -19.64% |
| 2018-12-31 | -32.28% |
| 2018-09-30 | 19.05% |
| 2018-06-30 | 29.92% |
| 2018-03-31 | 25.81% |
| 2017-12-31 | 30.22% |
| 2017-09-30 | -121.98% |
| 2017-06-30 | -206.30% |
| 2016-06-30 | -673.72% |
| 2016-03-31 | -125.34% |
| 2015-12-31 | -74.96% |
| 2015-09-30 | -131.52% |
| 2015-06-30 | -74.94% |
| 2015-03-31 | -151.64% |
| 2014-12-31 | -165.35% |
| 2014-09-30 | -213.04% |
| 2014-06-30 | -152.08% |
| 2014-03-31 | -135.94% |
| 2013-06-30 | -597.75% |
| 2013-03-31 | -182.19% |
| 2012-12-31 | -109.62% |
| 2012-09-30 | -131.98% |
| 2012-06-30 | -61.23% |
| 2012-03-31 | -31.15% |
| 2011-12-31 | -181.37% |
| 2011-09-30 | -67.45% |
| 2011-06-30 | -178.64% |
| 2011-03-31 | -378.01% |
| 2010-12-31 | -261.61% |
| 2010-09-30 | -140.02% |
| 2009-12-31 | -845.39% |
| 2009-09-30 | -376.62% |
| 2009-06-30 | -225.02% |
| 2008-12-31 | -316.35% |
| 2008-09-30 | -131.25% |
| 2008-06-30 | -92.53% |
| 2008-03-31 | -61.89% |
| 2007-12-31 | -41.37% |
| 2007-09-30 | -30.14% |
| 2007-06-30 | -22.88% |
| 2007-03-31 | -35.74% |
| 2006-12-31 | -63.91% |
| 2006-09-30 | -92.25% |
| 2006-06-30 | -96.67% |
| 2006-03-31 | -83.38% |
| 2005-12-31 | -72.91% |
| 2005-09-30 | -219.62% |
| 2005-06-30 | -127.87% |
| 2005-03-31 | -92.06% |
| 2004-12-31 | -61.33% |
| 2004-09-30 | -371.65% |
| 2004-06-30 | -69.64% |
| 2004-03-31 | -19.44% |
| 2003-12-31 | -776.06% |
| 2003-09-30 | -110.61% |
| 2003-06-30 | -101.38% |
